While FGFR2 amplification in gastric carcinomas had a prognostically unfavorable effect in the primary gastric cancer group (p = 0.005), which was not detectable in the neoadjuvant treated group, this effect was not measurable in any subgroup of esophageal adenocarcinomas. This evidence concerns the gene FGFR2 and gastric carcinoma.